{"changes":[{"companyHref":"/c/myrtellegtx-com","date":"2026-09-25","documentUrl":null,"domain":"myrtellegtx.com","fact":"latest round","name":"Myrtelle Inc.","new":{"amountUsd":55162634,"date":"2025-12-23","lead":null,"type":null},"old":{"amountUsd":55162634,"date":"2025-12-23","lead":null,"type":"seed"},"publisher":"sec-edgar","reason":null,"retrievedAt":"2026-06-05","slug":"myrtellegtx-com","status":"attributed","url":"https://whoraisedwhat.com/c/myrtellegtx-com"}],"country":"US","description":"Myrtelle develops gene therapies for myelin-based neurological disorders such as leukodystrophies that have few existing treatments. It serves patients with rare genetic white matter diseases of the central nervous system, with Canavan disease as its lead program.","domain":"myrtellegtx.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"biotechnology","investors":[],"lat":40.712728,"lng":-74.006015,"location":"New York, New York","name":"Myrtelle Inc.","rounds":[{"amountQuarantined":false,"amountUsd":55162634,"currency":"USD","date":"2025-12-23","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-06-05","status":"attributed","url":null},"status":"attributed","type":null,"url":null}],"slug":"myrtellegtx-com","sources":[{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-06-05","status":"attributed","url":null},{"fact":"existence","publisher":"myrtellegtx.com","retrievedAt":"2026-06-05","status":"self-reported","url":"https://myrtellegtx.com"},{"fact":"description","publisher":"myrtellegtx.com","retrievedAt":"2026-06-05","status":"self-reported","url":"https://myrtellegtx.com"}],"stage":null,"techStack":["addtoany","addtoany share buttons 1.1","contact form 7 6.1.5","facebook pixel","jquery 3.7.1","jquery migrate 3.4.1","mysql","nginx","php","pixelyoursite","python","slick"],"totalRaisedUsd":55162634,"updatedAt":"2026-06-05"}